Will I need maintenance therapy?

 

Ask a Question

Q: Will I need maintenance therapy?

A: Your doctor may advise that you receive on-going medication after your original treatment ends. This is called maintenance therapy. It helps keep certain cancers in remission and supports the continued effectiveness of your original treatment.

Whether you will have maintenance therapy or not depends upon the type of cancer you had and how it was treated. You may receive a long-standing medication or one that is undergoing clinical trials. Talk with your health care team about what type of posttreatment therapy you'll be on, the schedule you'll need to follow, and any possible side effects you should watch for.

Many patients do not receive maintenance therapy after completion of initial treatment. This can be a difficult time emotionally because questions come to your mind such as "If I don't receive any more treatment, will the cancer come back?" Discuss your feelings with your health care team. These are normal feelings and your health care team can help get you through this time of transition.
--Bernice Crook, RN, OCN

Here are some questions to ask about posttreatment care.

Latest Cancer News
Removing small colon polyps costly, unnecessary

November 20, 2008 — NEW YORK (Reuters Health) - The surgical removal of small colon polyps found during computed tomography imaging of the colon, or CT colonography, is costly and unnecessary, according to a new study.

Avastin® Linked with Increased Risk of Blood Clots

November 20, 2008 — According to a combined analysis of previously published studies, cancer patients who use Avastin® (bevacizumab) may have an increased risk of venous thromboembolism (a blood clot in a vein). These results were published in the Journal of the American Medical Association.

Addition of Avastin® to Paraplatin®, Taxol®, and Erbitux® Promising for Advanced NSCLC

November 20, 2008 — Researchers affiliated with the Southwest Oncology Group have reported that the four-drug combination of chemotherapy agents Paraplatin® (carboplatin) and Taxol® (paclitaxel) plus targeted therapies Avastin® (bevacizumab) and Erbitux® (cetuximab) is safe and may improve survival in patients with advanced non–small cell lung cancer (NSCLC). The details of this study were presented at the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology November 13-15.

Select news items provided by Reuters Health